



CorPath[®] Robotic-Assisted Peripheral Vascular Intervention Trial Data to be Presented at 37th Charing Cross Conference in London

Waltham, MA – April 29, 2015 – [Corindus Vascular Robotics \[OTCQB: CVRS\]](#), a leading developer of precision vascular robotics, announced today that Prof. Dr. Marianne Brodmann, a leading researcher at the Medical University of Graz in Graz, Austria will present data from the CorPath[®] Robotic-Assisted Peripheral Vascular Intervention Trial during the 37th Charing Cross Conference in London, UK on April 28 – May 1, 2015.

Launched in February of this year, the trial is assessing the safety and effectiveness of the CorPath System in recanalizing lower extremity arterial blockages during peripheral angioplasty procedures. The procedures were performed by Dr. Marianne Brodmann, Dr. Peter Kalmar, Dr. Florian Schmid, and Prof. Dr. Hannes Duetschmann, from the Medical University of Graz.

Dr. Brodmann will present her findings during “Evaluation of a robotic system for femoropopliteal interventions,” on Thursday, April 30 at 11:24 a.m.

Developed by Corindus Vascular Robotics, the CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to coronary angioplasty procedures. The CorPath System is currently indicated in the U.S. for Percutaneous Coronary Intervention (PCI) only. During the procedure, the interventional cardiologist sits in the radiation-shielded interventional cockpit and advances stents and guidewires with millimeter-by-millimeter precision.

For more information about the CorPath System, visit www.corindus.com.

About Corindus Vascular Robotics, Inc.

[Corindus Vascular Robotics, Inc.](#) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s FDA cleared CorPath 200 System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its technology with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Statements made in this press release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends

affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus' control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus' financial results is included from time to time in the "Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Corindus' periodic and current filings with the SEC, as well as those discussed under the "Risk Factors" and "Forward-Looking Statements" section of Corindus' Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on Corindus' website at <http://www.corindus.com/about-corindus/investor-relations>. Forward-looking statements speak only as of the date they are made and Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, that occur after that date.

###

Media Contacts:

Corindus Vascular Robotics

Brett Prince

(508) 653-3335 ext. 231

brett.prince@corindus.com

Emma Ludwin

203-504-8230 ext. 107

corindus@knbpr.com